Studying drug-resistant bacteria found in patients with leukemia
Tests bacteria resistant to carbapenem antibiotics in patients with acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Molecular Characterization of Carbapenemase-Producing Enterobacterales
Key facts
- Where
- Sohag, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for patients at Sohag Oncology Center who have an infection with carbapenem-resistant Enterobacterales, found by an antibiotic sensitivity test.
- Age
- 4 Years to 80 Years
- Sex
- All sexes can join.
- Disease stage
- An infection at any site with a carbapenem-resistant Enterobacterales organism.
- Biomarker or test result
- The organism found must be a carbapenem-resistant Enterobacterales, shown by an antibiotic sensitivity test.
Main reasons for not taking part
- Patients whose infection organism is not an Enterobacterales
- Patients whose organism is not carbapenem resistant
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 80 years old?
Source: NCT07116356, who can take part
Where in Egypt
- Sohag university, Faculty of medicineSohag, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sohag University
- Trial code
- NCT07116356
- Record updated
- 11 August 2025
- Original description
Bacterial infections with carbapenem resistant pathogens are one of the major threats in immunocompromised patients, especially among cancer patients .Furthermore, Gram negative pathogens are becoming increasingly prevalent and have become an ongoing global health concern .Emergence of Gram-negative pathogens, especially Enterobacterales that avert many of the human defense mechanisms are alarmingly increasing and most of these pathogens are resistant to many of the in-use antibiotics including carbapenems .Read full original descriptionShow less
Molecular Characterization of Carbapenemase-Producing Enterobacterales Isolated From Clinical Samples in Egypt
Bacterial infections with carbapenem resistant pathogens are one of the major threats in immunocompromised patients, especially among cancer patients .Furthermore, Gram negative pathogens are becoming increasingly prevalent and have become an ongoing global health concern .Emergence of Gram-negative pathogens, especially Enterobacterales that avert many of the human defense mechanisms are alarmingly increasing and most of these pathogens are resistant to many of the in-use antibiotics including carbapenems .
Inclusion: All patients admitted to Sohag Oncology Center have different infections and isolated organism one of carbapenem resistant enterobacterales detected by antibiotic sensitivity test.
Exclusion: All patients admitted to Sohag Oncology Center having infections in different sites and isolated organisms are not one of enterobacterales and not carbapenem resistant.